After a volatile year, advances in science, shifting competition and improving fundamentals are creating new opportunities for selective investors.
The first quarter of 2021 was challenging for investors in biotechnology, but Franklin Equity Group Portfolio Managers Evan McCulloch, Wendy Lam and Akiva Felt believe the second half of the year will likely bring welcome tailwinds for the industry.